Faeth Therapeutics, Inc.

FTH Healthcare Biotechnology

EPS
+78.2%
Free cash flow
−262.7%

Quarter to September 2026, against a year earlier

21.86 1.94 +9.74%
Market cap
$514.8M
P/E
0.0×
Fwd P/E
—
Dividend yield
—
F-score
n/a
Altman Z
n/a
Beneish M
n/a
Dividend safety
n/a
Sep '26 Jun '26 Mar '26 Dec '25 Older periods
ROE
(229.61%) (195.26%) 350.35% (74.01%)

+8 more TTM periods

ROA
(204.67%) (176.88%) (151.41%) (61.78%)
ROIC
0.00% 0.00% 0.00% 0.00%
Return on Tangible Assets
(126.71%) (109.16%) (97.03%) (121.61%)
Free Cash Flow per Share
(1.67) (6.00) (18.46) (16.03)
Free Cash Flow
(43.28) (33.86) (23.90) (20.22)
Other line items

Show all line items

Columns are period end dates · fundamentals updated 5 Nov 2026